Last reviewed · How we verify
Clopidogrel and Ticagrelor
This is a dual antiplatelet therapy combining two P2Y12 receptor antagonists that inhibit platelet aggregation through different binding mechanisms to reduce thrombotic events.
This is a dual antiplatelet therapy combining two P2Y12 receptor antagonists that inhibit platelet aggregation through different binding mechanisms to reduce thrombotic events. Used for Acute coronary syndrome (ACS) for reduction of thrombotic cardiovascular events, Secondary prevention of myocardial infarction and stent thrombosis.
At a glance
| Generic name | Clopidogrel and Ticagrelor |
|---|---|
| Sponsor | University of Patras |
| Drug class | Dual P2Y12 receptor antagonist / Antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Clopidogrel and ticagrelor are both P2Y12 receptor inhibitors that prevent platelet activation and aggregation, but they work through distinct mechanisms—clopidogrel is a prodrug requiring hepatic activation while ticagrelor is a direct-acting reversible inhibitor. The combination approach aims to achieve enhanced antiplatelet effects compared to monotherapy, potentially reducing cardiovascular events in acute coronary syndromes and other thrombotic conditions.
Approved indications
- Acute coronary syndrome (ACS) for reduction of thrombotic cardiovascular events
- Secondary prevention of myocardial infarction and stent thrombosis
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Gastrointestinal bleeding
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel and Ticagrelor CI brief — competitive landscape report
- Clopidogrel and Ticagrelor updates RSS · CI watch RSS
- University of Patras portfolio CI